Given that Rac1 inhibition reduced MM cell survival regardless of the p53 status, we examined whether it could increase MM cell sensitivity to existing drugs, including cereblon (CRBN) modulators and proteasome inhibitors, for the development of new therapeutic strategies. Here, RAC1 is linked to Miyoshi myopathy.